Huadong Pharmaceutical oral small molecule GLP-1 United States IND approved

On May 15th, China medicine (sz.000963) revealed that its small group glp-1 receptor stimulagent hdm1002 new drug clinical trial (indapplication) was approved by the United States fda for the clinical trial of the I phase of the adult type 2 diabetes. The public report shows that the hdm1002 is an innovative small sub-drug that is developed and has the global intellectual property rights of east China medicine, and is a complete excitant with oral activity, strong effect and high selective glp-1 receptor.Hdm1002 is a target of glp-1 receptor stimulant, GLP 1, which is used to improve the blood sugar control of adult type 2 diabetes (t2dmd) in clinical use. Many large clinical studies, such as the leaderwork sustainer rewind, have shown that glp-1 receptor agonists such as leilulin, somaru and verminopeptide are significant in reducing the risk of cardiovascular major events. Pre-clinical studies showed that the glp-1 receptor, induced by the glp-1 receptor, induced by the glp-1 receptor, was produced, with strong effect on improving sugar tolerance, sugar degradation and weight loss, and showing good safety.It is said that glp-1 products are growing rapidly and the market account rate is expected to continue to improve. According to the GLP 1ra report, which is based on the 2022 drug market life cycle research, the number of China's GLP 1ra market will grow from 5.6 billion yuan to $15.8 billion by 2030, with a combined growth rate of 140%. In 2022, the guanggon-1 stock market showed that the market was more than $20 billion, more than insulin, and had been dimagked by sugar and weight reduction. Socgen believes that as more and more glas 1 is approved, the overall permeability of glp-1 is expected to continue to improve.It is worth the fact that, as of now, there is no oral small group GLP 1 receptor stimulant drug listing, and the hdm1002 is approved in the United States, and will further increase the supply of products in the area of the treatment of east China medicine.Around GLP 1, east China medicine has been combined with the long-term and multi-target global innovative drugs and biological similar drugs, including oral, injection agents, and different products. In march, the indications of China's drug riraurin injection diabetes, which was listed in March of the year, was called liu-ping's, which opened China's first prescription on May 11.In addition, in the product pipeline of the research and development of the product pipeline, the global development of the global initiative of the global development of glam 1r/gcgr/fgf21r and the three-target accelerator dr10624 is in New Zealand for the clinical trial of the period. From Japan's scohiapharma,4as, the group introduced the glp-1r/gipr double target stimulative sco-094 and its derivatives products to treat diseases such as type 2 diabetes, obesity and non-alcoholic hepatitis (the). The injection of asperus peptide is in the phase I clinical trial phase.GLP 1 is one of the three hot targets of non-insulin treatment, and has been a target for the hottest in recent years. The glp-1 receptor agonist can reduce weight by stopping the loss of stomach and central appetite. The global drug giants, such as nord, lilly, sanofi and astrazeneca, have been in a distribution of weight loss indications.The application of ind hdm1002 in eastern China is approved by the fda, and it also marks an international recognition of the ability of domestic and domestic companies to develop their own research and development. In addition, the combination of the glomerular filter rate dynamic monitoring system and mb-102 injection of mb-102 injection, which is developed by eastern China medicine and American medibeacon,and the United States, is currently in the evaluation stage. The mb-102 injection, which is used in the system, is a global innovative drug that has been submitted by nda in April 2023.